Predicting How Ulcerative Colitis Patients Respond to Treatments
Develops a model predicting response to vedolizumab, ustekinumab or tofacitinib in ulcerative colitis.
Plain-language title generated from the registry record
Registry title: Prediction Model for Response to Biologics and Small Molecular Agent for UC
Key facts
- Where
- Seoul, South KoreaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 79 years old?
Source: NCT05186623, who can take part
Where in South Korea
- Asan Medical CenterSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Asan Medical Center
- Trial code
- NCT05186623
- Record updated
- 15 February 2022
- Original description
This prospective observational study is going to develop and validate a prediction model of response to biologic agents and small molecular agents for Korean patients with ulcerative colitis.Read full original descriptionShow less
Establishment of Prediction Model of Biologics and Small Molecular Agent for Patients With Ulcerative Colitis Using Longitudinal Data
This prospective observational study is going to develop and validate a prediction model of response to biologic agents and small molecular agents for Korean patients with ulcerative colitis.
Inclusion: Patients with an established diagnosis of ulcerative colitis based on clinical symptoms, endoscopic features and histopathologic features; Patients who are going to receive vedolizumab, ustekinumab, or tofacitinib treatment.
Exclusion: Patients who already received colectomy due to ulcerative colitis; Inflammatory Bowel Disease Unclassified; Not Korean ethnicity by family history.